Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated July 31, 2025, titled "Press Release on unaudited financial results for the quarter ended June 30, 2025".
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Lal Path Labs reported consolidated revenue of Rs 670 crore for Q1 FY26, up 11.3% from Rs 602 crore in Q1 FY25. EBITDA grew 13.1% to Rs 192 crore with margins improving to 28.7% from 28.2%. Profit after tax (PAT) jumped 24.3% to Rs 134 crore, with margins expanding sharply to 20.0% from 17.9%. EPS rose 24.4% to Rs 15.9. The board declared an interim dividend of Rs 6 per share. The company operates 298 clinical labs, 6,607 patient service centres, and 12,365 pick-up points as of March 2025.
Strong double-digit growth in revenue, EBITDA, and PAT with margin expansion signals healthy operational performance, likely to be viewed positively by investors. The interim dividend adds to shareholder returns.